scholarly journals Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy

2009 ◽  
Vol 11 (6) ◽  
Author(s):  
Nancy Dumont ◽  
Yongping G Crawford ◽  
Mahvash Sigaroudinia ◽  
Shefali S Nagrani ◽  
Matthew B Wilson ◽  
...  
Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2342 ◽  
Author(s):  
Lucie Brisson ◽  
Stéphanie Chadet ◽  
Osbaldo Lopez-Charcas ◽  
Bilel Jelassi ◽  
David Ternant ◽  
...  

The P2X7 receptor is an ATP-gated cation channel with a still ambiguous role in cancer progression, proposed to be either pro- or anti-cancerous, depending on the cancer or cell type in the tumour. Its role in mammary cancer progression is not yet defined. Here, we show that P2X7 receptor is functional in highly aggressive mammary cancer cells, and induces a change in cell morphology with fast F-actin reorganization and formation of filopodia, and promotes cancer cell invasiveness through both 2- and 3-dimensional extracellular matrices in vitro. Furthermore, P2X7 receptor sustains Cdc42 activity and the acquisition of a mesenchymal phenotype. In an immunocompetent mouse mammary cancer model, we reveal that the expression of P2X7 receptor in cancer cells, but not in the host mice, promotes tumour growth and metastasis development, which were reduced by treatment with specific P2X7 antagonists. Our results demonstrate that P2X7 receptor drives mammary tumour progression and represents a pertinent target for mammary cancer treatment.


1973 ◽  
Vol 71 (4_Suppl) ◽  
pp. S65 ◽  
Author(s):  
R. K. Wagner ◽  
L. Görlich ◽  
P. W. Jungblut

Author(s):  
Edward P. Gelmann ◽  
Connie Agnor ◽  
Marc E. Lippman

2011 ◽  
Vol 5 (3-4) ◽  
pp. 200-200
Author(s):  
Stefania Croci ◽  
Christian V. Recktenwald ◽  
Rudolf Lichtenfels ◽  
Giordano Nicoletti ◽  
Sven P. Dressler ◽  
...  

2015 ◽  
Author(s):  
Giulio Caravagna ◽  
Alex Graudenzi ◽  
DANIELE RAMAZZOTTI ◽  
Rebeca Sanz-Pamplona ◽  
Luca De Sano ◽  
...  

The genomic evolution inherent to cancer relates directly to a renewed focus on the voluminous next generation sequencing (NGS) data, and machine learning for the inference of explanatory models of how the (epi)genomic events are choreographed in cancer initiation and development. However, despite the increasing availability of multiple additional -omics data, this quest has been frustrated by various theoretical and technical hurdles, mostly stemming from the dramatic heterogeneity of the disease. In this paper, we build on our recent works on "selective advantage" relation among driver mutations in cancer progression and investigate its applicability to the modeling problem at the population level. Here, we introduce PiCnIc (Pipeline for Cancer Inference), a versatile, modular and customizable pipeline to extract ensemble-level progression models from cross-sectional sequenced cancer genomes. The pipeline has many translational implications as it combines state-of-the-art techniques for sample stratification, driver selection, identification of fitness-equivalent exclusive alterations and progression model inference. We demonstrate PiCnIc's ability to reproduce much of the current knowledge on colorectal cancer progression, as well as to suggest novel experimentally verifiable hypotheses.


2019 ◽  
Author(s):  
Runpu Chen ◽  
Steve Goodison ◽  
Yijun Sun

AbstractThe interpretation of accumulating genomic data with respect to tumor evolution and cancer progression requires integrated models. We developed a computational approach that enables the construction of disease progression models using static sample data. Application to breast cancer data revealed a linear, branching evolutionary model with two distinct trajectories for malignant progression. Here, we used the progression model as a foundation to investigate the relationships between matched primary and metastasis breast tumor samples. Mapping paired data onto the model confirmed that molecular breast cancer subtypes can shift during progression, and supported directional tumor evolution through luminal subtypes to increasingly malignant states. Cancer progression modeling through the analysis of available static samples represents a promising breakthrough. Further refinement of a roadmap of breast cancer progression will facilitate the development of improved cancer diagnostics, prognostics and targeted therapeutics.


2005 ◽  
Vol 114 (4) ◽  
pp. 572-578 ◽  
Author(s):  
Christophe Stove ◽  
Tom Boterberg ◽  
Veerle Van Marck ◽  
Marc Mareel ◽  
Marc Bracke

2020 ◽  
Vol 21 (S1) ◽  
Author(s):  
Simone Ciccolella ◽  
Mauricio Soto Gomez ◽  
Murray D. Patterson ◽  
Gianluca Della Vedova ◽  
Iman Hajirasouliha ◽  
...  

Abstract Background Cancer progression reconstruction is an important development stemming from the phylogenetics field. In this context, the reconstruction of the phylogeny representing the evolutionary history presents some peculiar aspects that depend on the technology used to obtain the data to analyze: Single Cell DNA Sequencing data have great specificity, but are affected by moderate false negative and missing value rates. Moreover, there has been some recent evidence of back mutations in cancer: this phenomenon is currently widely ignored. Results We present a new tool, , that reconstructs a tumor phylogeny from Single Cell Sequencing data, allowing each mutation to be lost at most a fixed number of times. The General Parsimony Phylogeny from Single cell () tool is open source and available at https://github.com/AlgoLab/gpps. Conclusions provides new insights to the analysis of intra-tumor heterogeneity by proposing a new progression model to the field of cancer phylogeny reconstruction on Single Cell data.


Sign in / Sign up

Export Citation Format

Share Document